Delving into the Latest Updates on Bayer Vital GmbH with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Cardiovascular Diseases

Urogenital Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	3
Infectious Diseases	3
Neoplasms	2
Nervous System Diseases	2
Immune System Diseases	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	6

Top 5 Target	Count

Bacterial DNA gyrase x Topoisomerase IV	1
AR x ER x MR x PR	1
COX(Cyclooxygenases)	1
AR x ER	1
fungal CYP51A1	1

AbstractIodinated contrast media (CM) have become indispensable in computed tomography (CT), angiography, and cardiac cathlab as well as in other X-ray-based procedures, for example in urology. In this context, iodinated CM are released into the environment in particular via patient excretions along with other trace substances. At the same time, the use of iodinated CM also involves CM leftovers as well as packaging and consumables.In order to reduce the discharge of iodinated CM into the environment and to promote efficient use of resources, awareness of the sustainable and responsible use of iodinated CM and associated consumables is essential. A number of effective measures can contribute to this in the short, medium, and long term. Based on the literature and quantitative data from our own routine, aspects of sustainability when dealing with CM in computed tomography are discussed in this review using the example of a hospital and a private practice.When planning and performing contrast-enhanced CT examinations, personalized CM protocols can make CM use more efficient. Some CM manufacturers offer recycling programs for CM leftovers. The collection of CM excretions after CM injections using urine bags might have a major impact on reducing the discharge of iodinated CM into the environment. In addition, responsible use of consumables and packaging material, in particular the use of multi-patient systems, can make a valuable contribution to waste avoidance and resource conservation. All of these measures can ultimately be fully effective in terms of protecting the environment and resources if they can be implemented on a broad basis. For this purpose, an even greater focus on the topic of sustainability among all parties involved is desirable.

04 Aug 2023·Journal of medical Internet research

Automated Electronic Health Record to Electronic Data Capture Transfer in Clinical Studies in the German Health Care System: Feasibility Study and Gap Analysis.

Article

Author: Mueller, Christian ; Mundhenke, Markus ; Herrmann, Patrick ; Junker, Erwin ; Remes, Bernhard ; Hastenteufel, Tobias ; Cichos, Stephan

BACKGROUNDData transfer between electronic health records (EHRs) at the point of care and electronic data capture (EDC) systems for clinical research is still mainly carried out manually, which is error-prone as well as cost- and time-intensive. Automated digital transfer from EHRs to EDC systems (EHR2EDC) would enable more accurate and efficient data capture but has so far encountered technological barriers primarily related to data format and the technological environment: in Germany, health care data are collected at the point of care in a variety of often individualized practice management systems (PMSs), most of them not interoperable. Data quality for research purposes within EDC systems must meet the requirements of regulatory authorities for standardized submission of clinical trial data and safety reports.OBJECTIVEWe aimed to develop a model for automated data transfer as part of an observational study that allows data of sufficient quality to be captured at the point of care, extracted from various PMSs, and automatically transferred to electronic case report forms in EDC systems. This required addressing aspects of data security, as well as the lack of compatibility between EHR health care data and the data quality required in EDC systems for clinical research.METHODSThe SaniQ software platform (Qurasoft GmbH) is already used to extract and harmonize predefined variables from electronic medical records of different Compu Group Medical-hosted PMSs. From there, data are automatically transferred to the validated AlcedisTRIAL EDC system (Alcedis GmbH) for data collection and management. EHR2EDC synchronization occurs automatically overnight, and real-time updates can be initiated manually following each data entry in the EHR. The electronic case report form (eCRF) contains 13 forms with 274 variables. Of these, 5 forms with 185 variables contain 67 automatically transferable variables (67/274, 24% of all variables and 67/185, 36% of eligible variables).RESULTSThis model for automated data transfer bridges the current gap between clinical practice data capture at the point of care and the data sets required by regulatory agencies; it also enables automated EHR2EDC data transfer in compliance with the General Data Protection Regulation (GDPR). It addresses feasibility, connectivity, and system compatibility of currently used PMSs in health care and clinical research and is therefore directly applicable.CONCLUSIONSThis use case demonstrates that secure, consistent, and automated end-to-end data transmission from the treating physician to the regulatory authority is feasible. Automated data transmission can be expected to reduce effort and save resources and costs while ensuring high data quality. This may facilitate the conduct of studies for both study sites and sponsors, thereby accelerating the development of new drugs. Nevertheless, the industry-wide implementation of EHR2EDC requires policy decisions that set the framework for the use of research data based on routine PMS data.

100 Deals associated with Bayer Vital GmbH

Login to view more data

100 Translational Medicine associated with Bayer Vital GmbH

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Approved

6

2

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Nimodipine ( Cav2.1 )	Nerve injury More	Approved
Aspirin ( COX )	Migraine Disorders More	Approved
Moxifloxacin Hydrochloride ( Bacterial DNA gyrase x Topoisomerase IV )	Bacterial Infections More	Approved
Clotrimazole ( fungal CYP51A1 )	Tinea More	Approved
Drospirenone/Estradiol ( AR x ER x MR x PR )	Vascular Diseases More	Approved